Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 3/20 | 0.31 |
| ▸ | LTA4H | P09960 | 2/20 | 0.31 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205718 | 0.93 | FKBP1A (0.33) | POLBFKBP1AACEAADATLMNA | |
| SCHEMBL7201093 | 0.86 | DPP4 (0.30) | SMN1; SMN2 | |
| SCHEMBL7199835 | 0.86 | OPRM1 (0.32) | ALDH1A1OPRM1FKBP1A | |
| SCHEMBL7202834 | 0.85 | USP2 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7201819 | 0.85 | MEN1 (0.30) | ALDH1A1MEN1KMT2A | |
| SCHEMBL7199832 | 0.84 | LTA4H (0.33) | ALDH1A1MEN1KMT2ASMN1; SMN2ACE | |
| SCHEMBL7201776 | 0.83 | — | — | |
| SCHEMBL7201125 | 0.82 | — | — | |
| SCHEMBL7203915 | 0.82 | ADRA1D (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL7202223 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | claimed |
| EP-1234834-A1 | 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | claimed |
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | SERPINB1, ELANE, MMP8 | ALDH1A1 597/4885MEN1 3608/4885POLB 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.